Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 6/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016601 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL895376 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3374799 | 0.89 | ALDH1A1 (0.74) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3374795 | 0.89 | ALDH1A1 (0.74) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL20683505 | 0.86 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL6475964 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAATSHRCPB1CTSL | |
| SCHEMBL6475969 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAATSHRCPB1CTSL | |
| SCHEMBL9885094 | 0.84 | ALDH1A1 (0.78) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL15944807 | 0.84 | ALDH1A1 (0.78) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL7286285 | 0.84 | ALDH1A1 (0.78) | ALDH1A1GAATSHREPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-7612094-B2 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN MA INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1499308-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087304-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | ALDH1A1 2967/4885GAA 4605/4885TSHR 543/4885 |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ALDH1A1 1326/4885GAA 694/4885TSHR 634/4885 |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | ALK, ACVR1, ACVRL1 | ALDH1A1 113/4885GAA 782/4885TSHR 1682/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ALDH1A1 1326/4885GAA 694/4885TSHR 634/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ALDH1A1 1326/4885GAA 694/4885TSHR 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.